1. Chronic myelogenous leukemia.
- Author
-
O'Brien S, Berman E, Bhalla K, Copelan EA, Devetten MP, Emanuel PD, Erba HP, Greenberg PL, Moore JO, Przepiorka D, Radich JP, Schilder RJ, Shami P, Smith BD, Snyder DS, Soiffer RJ, Tallman MS, Talpaz M, and Wetzler M
- Subjects
- Algorithms, Antimetabolites, Antineoplastic therapeutic use, Antineoplastic Agents therapeutic use, Antineoplastic Agents toxicity, Benzamides, Cell Transformation, Neoplastic, Chromosome Breakage, Chromosomes, Human, Pair 22, Chromosomes, Human, Pair 9, Cytarabine therapeutic use, Disease Progression, Drug Interactions, Gene Fusion, Hematopoietic Stem Cell Transplantation, Humans, Imatinib Mesylate, Interferons therapeutic use, Karyotyping, Leukemia, Myelogenous, Chronic, BCR-ABL Positive etiology, Leukemia, Myelogenous, Chronic, BCR-ABL Positive pathology, Piperazines therapeutic use, Piperazines toxicity, Pyrimidines therapeutic use, Pyrimidines toxicity, Recombinant Fusion Proteins chemistry, Recombinant Fusion Proteins metabolism, Remission Induction, Secondary Prevention, Translocation, Genetic, Transplantation, Homologous, Cytogenetic Analysis, Hematopoietic Stem Cells cytology, Leukemia, Myelogenous, Chronic, BCR-ABL Positive genetics, Leukemia, Myelogenous, Chronic, BCR-ABL Positive therapy, Practice Guidelines as Topic standards
- Published
- 2005
- Full Text
- View/download PDF